L1, a neuronal cell adhesion receptor of the immunoglobulin-like protein family is expressed in invading colorectal cancer (CRC) cells as a target gene of Wnt/b-catenin signaling. Overexpression of L1 in CRC cells enhances cell motility and proliferation, and confers liver metastasis. We recently identified ezrin and the IkB-NF-kB pathway as essential for the biological properties conferred by L1 in CRC cells. Here, we studied the underlying molecular mechanisms and found that L1 enhances ezrin phosphorylation, via Rho-associated protein kinase (ROCK), and is required for L1-ezrin co-localization at the juxtamembrane domain and for enhancing cell motility. Global transcriptomes from L1-expressing CRC cells were compared with transcriptomes from the same cells expressing small hairpin RNA (shRNA) to ezrin. Among the genes whose expression was elevated by L1 and ezrin we identified insulin-like growth factor-binding protein 2 (IGFBP-2) and showed that its increased expression is mediated by an NF-kB-mediated transactivation of the IGFBP-2 gene promoter. Expression of a constitutively activated mutant ezrin (Ezrin567D) could also increase IGFBP-2 levels in CRC cells. Overexpression of IGFBP-2 in CRC cells lacking L1-enhanced cell proliferation (in the absence of serum), cell motility, tumorigenesis and induced liver metastasis, similar to L1 overexpression. Suppression of endogenous IGFBP-2 in L1-transfected cells inhibited these properties conferred by L1. We detected IGFBP-2 in a unique organization at the bottom of human colonic crypts in normal mucosa and at increased levels throughout human CRC tissue samples co-localizing with the phosphorylated p65 subunit of NF-kB. Finally, we found that IGFBP-2 and L1 can form a molecular complex suggesting that L1-mediated signaling by the L1-ezrin-NF-kB pathway, that induces IGFBP-2 expression, has an important role in CRC progression.
INTRODUCTION
Aberrant activation of Wnt/b-catenin target genes has a key role during both early and later phases of human colorectal cancer (CRC) development. 1, 2 In recent studies, we identified members of the immunoglobulin-like cell adhesion receptors (Nr-CAM and L1), mostly known for their function in nerve cells, 3, 4 but also in many cancer cell types, 5 as target genes of b-catenin-TCF signaling in CRC cells. 6, 7 We detected L1 in a subpopulation of cells at the invasive front of CRC tissue displaying nuclear b-catenin localization. 7 We further found that the expression of L1 in human CRC cells, lacking endogenous L1, confers enhanced motility and metastasis to the liver in a mouse metastasis model. 8 Our studies indicated that a large number of genes induced by L1 in cultured CRC cell lines are also expressed a higher levels in human CRC tissue samples, as revealed by gene expression microarray profile comparisons. 8 An analysis of the signaling pathways that are involved in L1-mediated CRC cell metastasis showed that the cytoskeletal protein ezrin and the NF-kB pathway are both required for conferring metastatic capacities by L1. 9 Interfering with NF-kB signaling either by various means or by suppressing ezrin levels, both inhibited the capacity of L1 to confer metastatic abilities in human CRC cell lines. The mechanism of this L1-mediated signaling involves the sequestration (by L1) of ezrin and the inhibitor of kB (IkB) into a submembrane multi-molecular complex that results in enhanced phosphorylation and proteasomal degradation of IkB followed by nuclear translocation and increased NF-kB target gene expression. 9 Immunohistochemical studies of human CRC tissue samples showed that L1, ezrin and the phosphorylated NF-kB p65 subunit co-localize in cells at the invasive edge of human CRC tumors. 9 In the present study, we examined the mechanisms by which L1 activates ezrin and used global gene expression analysis by which we identified insulin-like growth factor-binding protein 2 (IGFBP-2) as an ezrin-regulated and NF-kB target gene that is activated in response to this signaling pathway. We determined the function of IGFBP-2 in L1-mediated CRC progression.
RESULTS

L1 induces ezrin phosphorylation by ROCK that is required for L1
and ezrin co-localization and enhanced CRC cell motility Ezrin can be found in a closed (inactive) and in an open (active) conformation that is regulated by phosphorylation ( Figure 1a ).
cell types an increase in ezrin phosphorylation when L1 levels were elevated ( Figure 1a ). As threonine phosphorylation at amino acid 567 of ezrin results in the folding of ezrin into an open/active conformation (Figure 1a) , 13 we used a threonine (T) to aspartic acid (D) substitution at position 567 (567D) to mimic a constitutively active form of ezrin. We also used an ezrin with a substitution of threonine to alanine (A) to mimic an inactive ezrin form (567A) that cannot be phosphorylated. Stable expression of these ezrin constructs into clones of Ls174T CRC cells, expressing endogenous ezrin, resulted in an increase in ezrin phosphorylation in cell clones harboring the 567D ezrin (Figure 1b , lanes 3 and 4 compared with control, lanes 1 and 2) and a much lower phosphorylation level of ezrin in clones expressing the 567A form of ezrin (Figure 1b , lanes 5 and 6). In accordance with these results, the staining for phosphorylated ezrin in cell protrusions and in the cytoplasm was much stronger in the 567D CRC cell clones and was very low in cells expressing the 567A mutant ezrin (Figure 1c) .
We determined whether increasing the activating phosphorylation of ezrin in CRC cells could mimic some of the effects conferred by L1 expression in CRC cells. We found that similar to L1 expression, transfection with ezrin 567D results in increased cell motility as determined by the rate of wound closure in a confluent monolayer of cells, whereas the inactive 567A form of ezrin was unable to induce such change in motility that remained similar to that of control Ls174T cells (Figure 1d) .
A dynamic 567T ezrin phosphorylation by protein kinase C (PKC) and ROCK 14, 15 regulates the association of ezrin with the actin cytoskeleton and membrane receptors. 11 We wished to determine which of these kinases are regulating ezrin phosphorylation in L1-expressing CRC cells. We determined the level of ezrin phosphorylation in the presence of increasing concentrations of PKC or ROCK inhibitors and found that whereas ezrin phosphorylation is gradually reduced when the levels of the ROCK inhibitor are increased (Figure 2a , lanes 5-7 compared with control, lane 1), increasing the PKC inhibitor levels had no effect on the extent of ezrin phosphorylation in L1-expressing cells ( Figure 2a , lanes 2-4, compared with lane 1). The inhibition of ROCK in L1-expressing cells also disrupted the recruitment of ezrin to cell-cell contacts containing L1 (Figure 2b ), but had no effect on the levels of L1 or ezrin (Figure 2a) . Moreover, the increase in L1-mediated cell motility in CRC cells was significantly reduced when ROCK was inhibited, but not when the PKC inhibitor was used (Figure 2c ). The motility of CRC cells that were not transfected with L1 was not significantly affected when either PKC or the ROCK inhibitor were applied (Figure 2c) , further emphasizing the importance of ROCK in the phosphorylation-dependent activation of ezrin that is involved in L1-mediated increase in cell motility.
Genes induced by L1 that involve signaling by ezrin We have previously identified a signaling complex between L1, ezrin and IkB that is required for L1-mediated induction of CRC cell motility and metastasis. 9 To identify downstream target genes of L1-mediated signaling that involve ezrin, we conducted DNA microarray gene expression analyses using Affymetrix GeneChips. We searched for genes whose transcription was significantly altered in CRC cell clones transfected with L1 þ shRNA to ezrin, in comparison with cells overexpressing L1. We compared these L1 induces IGFBP-2 by ezrin and NF-kB in colon cancer cells A Ben-Shmuel et al patterns of gene expression to empty vector transfected Ls174T cells. By this approach, we expected to find genes whose expression is dependent on ezrin in L1-transfected CRC cells. Table 1 contains the lists of genes whose levels were increased or decreased by at least twofold. The RNA levels of some of these genes were also determined by quantitative RT-PCR (Figure 3a) and by semi-quantitative RT-PCR followed by agarose gel electrophoresis (Figure 3b) . A gene that caught our interest was IGFBP-2, as a positive correlation between serum IGF-I and IGFBP-2, and the presence of colon adenomas was already reported, 16 and IGFBP-2 levels were reported to be increased in the blood of patients in many types of human cancer. 17 To examine whether IGFBP-2 is elevated by L1-ezrin signaling, we determined the levels of IGFBP-2 in CRC cell clones stably transfected with either L1 or L1 and a dominant negative ezrin (L1 þ dnEz), 9 and in cells transfected with a mutant L1-Y1151A that lacks the ability to form a complex with ezrin. 9 As expected, we found higher levels of IGFBP-2 in L1-expressing cells compared with control cells (Figure 3c , lanes 1 and 2 compared with lanes 3 and 4). Moreover, in cells expressing L1 where L1-ezrin signaling is impaired, the level of IGFBP-2 was reduced to that observed in control cells (Figure 3c , lanes 5-7 compared with lanes 3 and 4). We found a similar increase in IGFBP-2 after transfection with L1 in clones of two other CRC cell lines, DLD-1 and HCT116 (Figure 3d ), indicating that L1 elicits enhanced IGFBP-2 expression in various CRC cell lines. Moreover, we detected an increase in IGFBP-2 levels also in CRC cell clones transfected with the activated form of ezrin (Ezrin567D, Figure 3e , lanes 3 and 4 compared with lane 2), similar to that elicited by L1 (Figure 3e, lane 1) . CRC cells expressing the inactive ezrin form (Ezrin567A) were ineffective in changing IGFBP-2 levels (Figure 3e , lanes 5 and 6). Together, these results demonstrate that IGFBP-2 expression is induced in CRC cells by an ezrin-phosphorylation-mediated signaling pathway that depends on an interaction between L1 and ezrin.
IGFBP-2 is a target gene of NF-kB that is induced by L1 in CRC cells As our previous studies suggested that L1 and ezrin-mediated signaling involve the activation of the NF-kB pathway, 9 we asked whether NF-kB directly regulates the transcription of the IGFBP-2 gene. We used plasmids containing sequences proximal to the IGFBP-2 transcription start site, ranging from 0.2 kb to 1.2 kb, that are linked to the luciferase gene ( Figure 4a , right panel). HEK 293T cells were co-transfected with plasmids coding for L1, the NF-kB p65 subunit, or with the empty vector (pcDNA3), and with the IGFBP-2 reporter plasmid, or with PGL3 (the empty vector), and luciferase activity was determined ( Figure 4a ). Cells co-transfected with L1 or p65 displayed higher levels of IGFBP-2 transactivation compared with cells transfected with the control pcDNA3 vector, but this was only observed with the 1.2 kb IGFBP-2 promoter construct, indicating that induction of IGFBP-2 activity by L1 and NF-kB signaling is restricted to a site between À 834 and À 1274 upstream from the transcription start site. Searching in the IGFBP-2 gene sequence for NF-kB consensus-binding sites (using the Lalign program), we identified three putative NF-kB-binding sites: one in the promoter ( À 1180 bp upstream of the transcription start site) and two additional sites in intron 1 (Figure 4b , scheme). By chromatin immunoprecipitation we asked whether the NF-kB p65 subunit binds to IGFBP-2 regulatory sequences. We used nuclear lysates from Ls174T-L1 and HEK 293T cells transfected with p65 and a primer set that amplifies the three putative NF-kB-binding sequences and a control site lacking such sequences (Figure 4b , scheme). This analysis revealed that NF-kB binds to the first and third sites on the IGFBP-2 promoter in both cell types ( Changes in IGFBP-2 levels regulate CRC cell motility and proliferation After demonstrating that an L1-ezrin-NF-kB signaling pathway induces IGFBP-2 gene expression in CRC cells, we wished to determine to what extent changes in IGFBP-2 levels mimic the physiological effects conferred by L1 in CRC cells. For this, we stably transfected IGFBP-2 cDNA into CRC Ls174T cells (that lack endogenous L1) to obtain cell clones overexpressing IGFBP-2 ( Figure 5a , lanes 5 and 6), and asked whether IGFBP-2 has the ability to promote cell proliferation under stressful conditions (in the absence of serum). We found that IGFBP-2 overexpressing CRC cell clones continued to grow in the absence of serum, similar to cells overexpressing L1 (albeit to a lesser extent), whereas cells expressing the empty vector did not grow under such conditions ( Figure 5b ). We also examined the motile properties of CRC cells overexpressing IGFBP-2 and found that two independently isolated Ls174T clones overexpressing IGFBP2 displayed an increase in the capacity to close artificial wounds as compared with control cells (Figure 5c , white bars, compared with gray bar).
In addition to IGFBP-2 overexpression, we also suppressed the endogenous levels of IGFBP-2 in L1-expressing CRC cells (Figure 5a, lanes 3 and 4) to determine whether the L1-mediated capacity to promote cell motility and proliferation is dependent on endogenous IGFBP-2 levels. We found that cells expressing both L1 and shRNA to IGFBP-2 displayed a slower growth rate in the absence of serum, similar to control cells expressing the empty vector, whereas cells expressing L1 maintained higher growth rates (Figure 5d ). Analysis of the motile properties of CRC cells expressing both L1 and shRNA to IGFBP-2 showed that such cells display a decreased capacity to close artificial wounds compared with cells expressing L1 (Figure 5e , white bars compared with IGFBP-2 overexpression in CRC cells enhances tumorigenesis and induces liver metastasis The results described above indicated that increasing IGFBP-2 levels in CRC cells mimics some of the properties conferred by L1 transfection, whereas the suppression of IGFBP-2 levels in L1-transfected cells inhibits these effects. We wished to determine whether IGFBP-2 transfection alone enhances the tumorigenic and metastatic properties of CRC cells similar to L1 overexpression. Two independently isolated Ls174T cell clones overexpressing IGFBP-2 ( Figure 5a , lanes 5 and 6), a cell clone transfected with L1
and a cell clone transfected with the empty vector were injected subcutaneously into four different sites in each of five mice. The size and weight of the developing tumors was determined (Figures 6a and b) . The results showed that both CRC cell clones overexpressing IGFBP-2 formed larger tumors compared with control (empty vector transfected cells), and these tumors were similar in size to those formed by L1 overexpression (Figures 6a  and b) . We have also determined the capacity of IGFBP-2-overexpressing cells to form liver metastases when injected into the spleen of nude mice, as we found previously with L1-transfected CRC cells. 9 IGFBP-2 transfected CRC cells conferred liver metastasis (Figure 6c ) in B50% of the injected mice, a result somewhat lower than 75% obtained by L1 transfection (Figure 6e) . 9 We have also determined the role of endogenous (Figure 6d ) and metastatic potential conferred by L1 (Figure 6e) . Thus, the increase in IGFBP-2 induced by L1 transfection in CRC cells constitutes an essential part of the tumorigenic properties conferred by L1. We analyzed by immunohistochemistry the localization of IGFBP-2 in human CRC tissue samples and found that IGFBP-2 displays a very restricted distribution at the lower part of the colonic crypts in normal colonic mucosa, while in the tumor tissue (in B50% of the cases) IGFBP-2 staining was more pronounced and present in most carcinoma cells (but not in the stroma), indicating increased levels of IGFBP-2 in the tumor tissue (Figure 6f ). In addition, we found that many of the tumor cells expressing the phosphorylated form of the NF-kB p65 subunit (pp65) in their nuclei (Figure 6g , lower panel) also expressed IGFBP-2 at the cell surface (Figure 6g , arrowheads, upper panel) supporting the notion that IGFBP-2 expression by NF-kB-driven transactivation is a characteristic feature of human CRC cells in vivo.
L1 can form a complex with IGFBP-2 IGFBP-2 is mostly a secreted protein also in CRC cells as indicated by comparing its level in cell lysates and in conditioned medium (CM) from the same cells (Figure 7a) . The CM from IGFBP-2-transfected cells was active in promoting the motility of CRC cells, even in the absence of L1, or in CRC cells where the endogenous IGFBP-2 levels were suppressed by shRNA (Figure 7b ), indicating that IGFBP-2 in the CM has a role in enhancing CRC cell motility. L1 is a transmembrane receptor that is also shed by metalloprotease activity into the culture medium and can bind to multiple partners via its extracellular domain. 5, 7 We asked whether IGFBP-2 forms a molecular complex with L1 when L1 and IGFBP-2 are coexpressed in the same cells. For this, we transfected HEK 293T cells with plasmids encoding for L1 together with the IGFBP-2 cDNA (Figure 7c, lane 7) , and conducted co-immunoprecipitation assays with either anti-L1 (Figure 7c, lanes 2, 3, 5 ) or with anti-IgG (as control) (Figure 7c , lane 1), followed by western blot analysis. We also co-transfected L1 with Myc-tagged Twist (Figure 7c , lane 6) as control for an unrelated protein for co-immunoprecipitation. We found that the anti-L1 antibody co-precipitated L1 with IGFBP-2 ( Figure 7c, lane 3) , but not L1 with Myc-Twist (Figure 7c, lane 2) , or when a non-immune IgG was used (Figure 7c, lane 1) . This indicates that L1 can form a molecular complex with IGFBP-2 and suggests the possibility that L1 and IGFBP-2 may act together in L1-mediated signaling in CRC cells (Figure 7d) .
DISCUSSION
In the present study, we identified molecular mechanisms contributing to the induction of metastasis in CRC cells by L1. We detected ezrin phosphorylation by ROCK, specifically on Threonine567, as a key event in the recruitment of ezrin by L1 to the submembrane region. Overexpression of an activated form of ezrin (Ezrin567D) could mimic some of the effects conferred by L1 in CRC cells, including enhanced motility and increased expression of IGFBP-2. The introduction into CRC cells of an inactive mutant ezrin at this position (Ezrin567A) was unable to cause these L1 induces IGFBP-2 by ezrin and NF-kB in colon cancer cells A Ben-Shmuel et al changes, similar to the inhibition of ezrin phosphorylation by a ROCK inhibitor. These results support the important role of ROCKmediated phosphorylation of ezrin on Threonine567 in the biological activities of ezrin as also reported in other types of cancer cells. 18, 19 As the induction of CRC metastasis to the liver by L1 is mediated by ezrin and NF-kB signaling, 9 we wished to determine the target genes involved in this process. We used global gene expression analyses to identify genes that are induced by L1 and whose levels are suppressed in L1-transfected cells by shRNA to ezrin. One of the genes induced under these conditions was IGFBP-2, a major regulator of insulin-like growth factors I and II (IGF-I/II) that competes with the IGF-receptor for IGF binding. 17, 20 IGFBP-2 was also reported to transmit signals independently of IGF-I/II by affecting cell adhesion via integrin binding, [21] [22] [23] and even to act in the cell nucleus. 24 In addition, increased levels of IGFBP-2 in the serum of cancer patients was shown in a variety of human cancers to be an indication of poor prognosis, [25] [26] [27] [28] [29] including CRC patients. [30] [31] [32] [33] A recent study identified IGFBP-2 signaling as an important factor in the recruitment of endothelial cells in metastatic breast cancer by a miR-126-dependent mechanism. 34 By chromatin immunoprecipitation and gene promoter reporter activation we showed that IGFBP-2 transactivation is enhanced by NF-kB, in agreement with the increase in IGFBP-2 protein levels in p65-overexpressing cells. These data were supported by the colocalization of IGFBP-2 and the phosphorylated p65 (p-p65) NF-kB subunit in human CRC tissue samples, but not in normal human colonic mucosa that displayed a very restricted expression of IGFBP-2 in the lower part of the crypts (Figures 6f and g ) and no p-p65 staining. 9 This increase in IGFBP-2 was dependent on ezrin as shRNA to ezrin in L1-transfected cells blocked the increase in IGFBP-2. Moreover, expression of the activated form of ezrin (Ezrin567D), but not the inactive ezrin (Ezrin567A) form, induced an increase in IGFBP-2 levels in the absence of L1 (Figure 3e ). The significance of IGFBP-2 elevation in conferring tumorigenic properties was further supported by our results showing that IGFBP-2 overexpression was capable of reproducing all the properties observed with L1 overexpression, including enhanced motility, growth in the absence of serum, and increased tumorigenesis and liver metastasis, whereas suppression of endogenous IGFBP-2 levels in L1-transfected cells reversed the effects conferred by L1 (Figures 6a-e) . We also demonstrated that CM from IGFBP-2-overexpressing cells could promote the motility of CRC cells (even of cells where endogenous IGFBP-2 was suppressed) and demonstrated by co-immunoprecipitation a capacity of IGFBP-2 to form a molecular complex with L1. As both L1 and IGFBP-2 are shed (L1) or secreted (IGFBP-2) into the culture medium, this observation raises the possibility that L1 and IGFBP-2 may cooperate directly in signaling that brings about tumor progression. We are currently investigating this possibility.
In conclusion, these studies indicate that L1-mediated CRC invasion and metastasis includes IGFBP-2 as a key downstream 3  and 4) , L1, or an empty pcDNA3 vector was determined in triplicates during 5 days. (c) An artificial wound was introduced into confluent monolayers of the cell lines described in (b), and the rate of cell motility into the wound area was determined after 24 h as described in Figure 1d . (d) The proliferation (without serum) of Ls174T CRC cell clones expressing shRNA to IGFBP-2 (a, lanes 5 and 6) was determined in triplicates during 5 days. (e) The ability of the cell clones described in (d) to close a wound in a confluent monolayer was also measured.
L1 induces IGFBP-2 by ezrin and NF-kB in colon cancer cells A Ben-Shmuel et al target active in CRC cells by a molecular circuitry that includes ezrin phosphorylation by ROCK and NF-kB-mediated transactivation of IGFBP-2 ( Figure 7d ). As attempts of targeting cancer development by blocking IGFBP-2 activity [35] [36] [37] or ezrin phosphorylation 18 are already ongoing, we anticipate that further elucidation of the detailed molecular pathways by which L1 mediates human CRC metastasis will bring us closer to achieving this aim.
MATERIALS AND METHODS
Cell culture, proliferation, artificial wound closure and transfections HEK 293T, Ls174T, DLD-1 and HCT116 cells were grown as described. Ls174T-Ezrin567D, Ls174T-Ezrin567A, Ls174T-IGFBP-2 cells were maintained in medium containing neomycin (800 mg/ml), Ls174T-L1 þ shIGFBP-2 cells in medium with both neomycin (800 mg/ml) and puromycin (10 mg/ml), and Ls174T cells expressing inducible L1 12 in medium with zeocin (500 mg/ml) and blasticidine (10 mg/ml). L1 expression was induced with 1 mg/ml doxycycline. For cell growth assays, 10 4 cells/well were seeded in 24-well dishes and cell number determined in triplicates for 5 days. To collect the conditioned medium, Ls174T cells expressing L1, IGFBP-2 or L1 þ shIGFBP-2 were grown for 2 days in serum-free medium, and the secreted proteins were precipitated with 75% ethanol while the cell layer was lysed with radioimmunoprecipitation assay (RIPA) buffer.
Proteins from CM and cell lysate were re-suspended in equal volumes of Laemmli's sample buffer and analyzed by SDS-PAGE. An artificial wound was introduced into confluent cell cultures using a micropipette. The medium was replaced with fresh medium containing 0.35 mg/ml mitomycin-C to inhibit cell proliferation. Pictures were taken at 0 and 24 h after introducing the wound and percent wound closure was determined.
Transient transfection of HEK 293T cells was performed using the calciumphosphate method. Ls174T, DLD-1 and HCT116 cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
Plasmids
The wt L1 cDNA and L1 mutants were previously described. 38 Ezrin567D/A, dnEzrin, shEzrin and control shRNA expression vectors (pcDNA3, pCB6-EZtag and psiRNA GFP zeo, respectively) were obtained from Dr Monique Arpin (Institute Curie, Paris, France). For the ezrin shRNA targeting sequences see Table 2 . The pcDNA4/TO L1 expression vector was generated by cloning the L1 cDNA from the pcDNA3-L1 plasmid into the pcDNA4/TO tetracycline-inducible vector at the EcoRI/BamHI cloning Figure 7 . IGFBP-2 and L1 can form a molecular complex. (a) The levels of IGFBP-2 in an equivalent amount of Ls174T CRC cell protein (from the cell clones described in Figure 5a ) from both the cell layers and from 2 days CM was determined by western blotting. Tubulin served as protein loading control. (b) The motility of the cell lines described in Figure 5d was determined after 24 h in the presence of CM from cells transfected with IGFBP-2 or with shRNA to IGFBP-2 as described in Figure 1d . IGFBP-2 shRNA was prepared in pSUPER.puro according to the manufacturer's instructions (pSUPER.puro RNAi System, OligoEngine, Seattle, WA, USA) using the target sequences shown in Table 2 .
Luciferase reporter assays HEK 293T cells were transiently co-transfected in triplicates with 0.1 mg L1, p65 or pcDNA3 expression vector, together with 0.25 mg b-galactosidase plasmid and 0.25 mg IGFBP-2 promoter reporter plasmids in pGL3, or with 0.25 mg of empty pGL3. Cells were lysed 24 h after transfection, and luciferase and b-galactosidase levels were determined by the luciferase assay system (Promega, Fitchburg, WI, USA), b-galactosidase by adding 2 Â b-galactosidase solution (2 mM MgCl 2 , 100 mM b-mercaptoethanol and 1.33 mg/ml ortho-nitrophenyl b-galactoside) followed by 0.1 M Na 2 CO 3 to stop the reaction. Luciferase activity was normalized to b-galactosidase activity for transfection efficiency.
RT-PCR and quantitative real-time PCR RNA was isolated using EZ-RNA kit (Biological Industries, kibbutz Beit-Haemek, Israel). PCR was conducted using the sequences shown in Table 2 . Relative gene expression was calculated employing quantitative real-time PCR (qRT-PCR) with primers designed for EREG, AREG, IGFBP-2, HSPA1A and HMGCS2 (see Table 2 ). qRT-PCR was performed on the ABgene thermocycler with the ABsolute SYBRgreen ROX mix (ABgene, Epsom, UK). Triplicates of 1 ng cDNA template and 500 nM gene-specific primers were used. The glyceraldehyde 3-phosphate dehydrogenase gene served to normalize for RNA levels. Primers were examined for efficiency, displaying an amplification slope of À 3.33 ± 0.3 and r 2 X0.98. Reverse transcription was started by incubating the samples at 95 1C for 15 min followed by quantitative PCR amplification cycles (95 1C for 20 s and 60 1C for 1 min for 40 cycles). Data analysis was conducted with the DDC T method with the ABgene thermocycler software. For semi-quantitative RT-PCR, the RT-PCR products were analyzed by agarose gel electrophoresis as described. 9 Chromatin immunoprecipitation assays Rabbit anti-p65 (sc-109, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was used for the immunoprecipitation and rabbit anti-IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) as control antibody. Chromatin immunoprecipitation was carried out as described, 39 with the exception that the DNA was purified using the PCR Purification Kit (Promega) and subjected to PCR with the specific primers shown in Table 2 .
Immunofluorescence and immunoblotting
Immunofluorescence and immunoblotting were carried out as described 9 using the following antibodies: rabbit anti-phospho-ezrin (Cell Signaling Technologies, Inc., Beverly, MA, USA no. 3141, 1:5000), mouse anti-ezrin (Sigma-Aldrich, St Louis, MO, USA, E8897, 1:5000), goat anti-IGFBP-2 (Santa Cruz sc-6001, 1:500), rabbit anti-L1 (gift from Dr Vance Lemmon, University of Miami, FL, USA, 1:5000) and mouse anti-a-tubulin (SigmaAldrich T9026, 1:200 000). In the ROCK and PKC inhibition experiments Ls174T-L1 cells were treated with increasing concentrations of the PKC inhibitor bisindolylmaleimide I at 10, 100, and 250 nM, or the ROCK inhibitor Y-27632 at 140 nM, 7, and 35 mM, for 24 h.
Immunohistochemistry
Immunohistochemistry was carried out on 25 paraffin-embedded human colorectal adenocarcinomas as described. 9 For IGFBP-2 detection, polyclonal goat anti-IGFBP-2 antibody (no. sc-6001, Santa Cruz, CA, USA, diluted 1:75) was used. Phosphorylated p65 (p-p65) staining was carried out as described. 9 The streptomycin/AB system was employed to detect antibody binding according to the manufacturer's protocol (Dako, Hamburg, Germany). Sections were counterstained with hemalaun (Merck, Darmstadt, Germany).
DNA microarrays
Two individually isolated Ls174T clones expressing L1 were compared with Ls174T cells expressing L1 þ shEzrin or the empty vector. Microarray analysis with RNA extracted from these cells was performed at the Weizmann Institute Microarray Facility on Affymetrix 1.0st GeneChips, and the chips were processed and the data analyzed as described. 8 Tumor growth and metastasis assays Tumor growth was induced by injecting subcutaneously 2.5 Â 10 6 cells in 200 ml phosphate-buffered saline into the flanks of nude mice (five mice per group). Control cells were injected into the opposite flank of the same mouse and tumors were removed and compared after 2-4 weeks. For metastasis assays, groups of 5-10 mice were injected with 1 Â 10 6 cells in 20 ml phosphate-buffered saline into the distal tip of the spleen. After 4-6 weeks the spleens and livers were removed as described. 8 
Statistics
Statistical significance was determined by the Fisher's exact test 40 for mouse metastasis experiments. Tumor mass was compared and significance determined by ANOVA. In wound closure studies, significance was determined using the non-paired Student's t-test. A P value of o0.05 was considered significant.
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